No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HQY240621C85000
- 0.42
- +0.02+5.00%
15min DelayClose Jun 14 16:00 ET
0.55High0.42Low
0.55Open0.40Pre Close6 Volume434 Open Interest85.00Strike Price304.00Turnover28.29%IV3.56%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.42Extrinsic Value100Contract SizeAmericanOptions Type0.2123Delta0.0982Gamma235.66Leverage Ratio-0.0764Theta0.0028Rho50.02Eff Leverage0.0303Vega
Intraday
- 5D
- 1D
News
Wasatch Small Cap Growth Strategy's Investment in HealthEquity (HQY) Paid Off in Q1
HealthEquity(HQY.US) Officer Sells US$813.3K in Common Stock
$HealthEquity(HQY.US)$ Officer Neeleman Stephen sold 9,564 shares of common stock on Jun 6, 7, 2024 at an average price of $85.0379 for a total value of $813.3K.Source: Announcement What is statement
Healthequity Insider Sold Shares Worth $813,302, According to a Recent SEC Filing
Stephen Neeleman, Director, Founder and Vice Chairman, on June 06, 2024, sold 9,564 shares in Healthequity (HQY) for $813,302. Following the Form 4 filing with the SEC, Neeleman has control over a tot
HealthEquity(HQY.US) Officer Sells US$2.13 Million in Common Stock
$HealthEquity(HQY.US)$ Officer Neeleman Stephen sold 25,036 shares of common stock on Jun 5, 2024 at an average price of $85.0556 for a total value of $2.13 million.Source: Announcement What is statem
Healthequity Insider Sold Shares Worth $2,129,452, According to a Recent SEC Filing
Stephen Neeleman, Director, Founder and Vice Chairman, on June 05, 2024, sold 25,036 shares in Healthequity (HQY) for $2,129,452. Following the Form 4 filing with the SEC, Neeleman has control over a
HealthEquity Is Maintained at Outperform by Raymond James
HealthEquity Is Maintained at Outperform by Raymond James
Comments
HealthEquity's high P/S ratio could possibly be due to market expectations for future growth. The current justification for the high ratio lies on the low chance of decreased revenues, which investors expect to uphold share price.
Despite expenses reducing earnings last year, HealthEquity's future outlook remains positive. Unusual items don't typically recur, suggesting underestimated earning potential. The firm returned to profitability this year.
Despite HealthEquity's revenue growth and share price rise over three years, short-term underperformance and negative five-year returns are concerning. Fundamental improvements are required for shareholder confidence. Analyst forecasts could shed light on the company's future.
Read more